Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN4461 in Generalized Lipodystrophy
NCT04159415Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of mibavademab in generalized lipodystrophy (GL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Absolute Change From Baseline in Hemoglobin A1c at 8 weeks, Absolute Change From Baseline in Fasting Glucose at 8 weeks and 2 more. Started Jan 2020; status: completed.
02
Drugs
mibavademab
03
Conditions
generalized lipodystrophy (GL)
Beyond the preview
Go deeper on NCT04159415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159415.